- Home
- AKTX vs ENGS Comparison
AKTX vs ENGS Comparison
Compare AKTX & ENGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- ENGS
- Stock Information
- Founded
- AKTX N/A
- ENGS 1998
- Country
- AKTX United States
- ENGS United Kingdom
- Employees
- AKTX N/A
- ENGS N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- ENGS
- Sector
- AKTX Health Care
- ENGS
- Exchange
- AKTX Nasdaq
- ENGS NYSE
- Market Cap
- AKTX 35.7M
- ENGS 29.8M
- IPO Year
- AKTX N/A
- ENGS 2025
- Fundamental
- Price
- AKTX $1.12
- ENGS $3.03
- Analyst Decision
- AKTX Strong Buy
- ENGS
- Analyst Count
- AKTX 1
- ENGS 0
- Target Price
- AKTX $5.00
- ENGS N/A
- AVG Volume (30 Days)
- AKTX 20.9K
- ENGS 562.6K
- Earning Date
- AKTX 08-18-2025
- ENGS 01-01-0001
- Dividend Yield
- AKTX N/A
- ENGS N/A
- EPS Growth
- AKTX N/A
- ENGS N/A
- EPS
- AKTX N/A
- ENGS N/A
- Revenue
- AKTX N/A
- ENGS $11,089,930.00
- Revenue This Year
- AKTX N/A
- ENGS N/A
- Revenue Next Year
- AKTX N/A
- ENGS N/A
- P/E Ratio
- AKTX N/A
- ENGS N/A
- Revenue Growth
- AKTX N/A
- ENGS 6.58
- 52 Week Low
- AKTX $0.85
- ENGS $1.36
- 52 Week High
- AKTX $4.40
- ENGS $10.24
- Technical
- Relative Strength Index (RSI)
- AKTX 44.73
- ENGS N/A
- Support Level
- AKTX $1.08
- ENGS N/A
- Resistance Level
- AKTX $1.15
- ENGS N/A
- Average True Range (ATR)
- AKTX 0.03
- ENGS 0.00
- MACD
- AKTX 0.00
- ENGS 0.00
- Stochastic Oscillator
- AKTX 57.14
- ENGS 0.00
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About ENGS ENERGYS GROUP LTD
Energys Group Ltd provides end-to-end customized solutions and services involving the retrofitting of existing infrastructure to reduce their CO2 emissions. The Company's customers include large national account end-users, including universities, schools, hospitals and electrical distributors in the United Kingdom.